Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vonicog Alfa (Recombinant Von Willebrand Factor) Treatment Outcomes in Von Willebrand Disease in the UK: a Retrospective Chart Review Study

NCT06433778 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06433778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06433778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vonicog Alfa (Recombinant Von Willebrand Factor) Treatment Outcomes in Von Willebrand Disease in the UK: a Retrospective Chart Review Study
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
December 16, 2021
Completion date
October 30, 2023
Enrollment
34 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease (vwd)